case_images: PMC10021297_01
case_images: (A) HE (x100); (B) Vimentin(+) (x100); (C) CD68(+) (x100); (D) CK(partial+) (x100).
case_images: pore-29-1610983-g001.jpg
case_images: PMC10021297_04_pore-29-1610983-g001.jpg
case_images: F1
case_images: Pathological sections from this patient were subjected to whole genome anslysis by second-generation sequencing (Sidi Precision Medicine, Illumina Nextseq500; 3DMed, Shanghai, China, http://www.3dmedcare.com), and the results demonstrated (Supplementary Table S1; Supplementary Figure S1) that 6 genetic mutations were associated with targeted therapy, prognosis and drug resistance.
case_images: PMC10021297_02
case_images: (A) HE (x100); (B) Vimentin(+) (x100); (C) CD68(focal +) (x100); (D) CK(focal +) (x100).
case_images: pore-29-1610983-g002.jpg
case_images: PMC10021297_04_pore-29-1610983-g002.jpg
case_images: F2
case_images: PARP inhibitor-related genes had no mutations (BRCA1/2 no mutations, HRD score 0 (Supplementary Figure S2)).
case_images: PMC10021297_03
case_images: (A) HE(x100); (B) Vimentin(+) (x100); (C) CD68(OGC+) (x100); (D) CK(+) (x100).
case_images: pore-29-1610983-g003.jpg
case_images: PMC10021297_04_pore-29-1610983-g003.jpg
case_images: F3
case_images: Immunotherapy-related gene mutations were observed negative PD-1 immunohistochemistry results (TPS <1%, CPS = 5) and a low tumor mutational burden (TMB) (Supplementary Figure S3A) at 3.35 Muts/Mb, which occur in less 76% of pancreatic cancer patients. Microsatellite analysis showed microsatellite stability (MSS) (Supplementary Figure S3B) and negative EBV test results.
case_images: PMC10021297_04
case_images: (A) HE (x100); (B) Vimentin(+) (x100); (C) CD68(+) (x100); (D) CK(partial+) (x100).
case_images: pore-29-1610983-g001.jpg
case_images: PMC10021297_04_pore-29-1610983-g001.jpg
case_images: F1
case_images: Pathological sections from this patient were subjected to whole genome anslysis by second-generation sequencing (Sidi Precision Medicine, Illumina Nextseq500; 3DMed, Shanghai, China, http://www.3dmedcare.com), and the results demonstrated (Supplementary Table S1; Supplementary Figure S1) that 6 genetic mutations were associated with targeted therapy, prognosis and drug resistance.
case_images: (A) HE (x100); (B) Vimentin(+) (x100); (C) CD68(focal +) (x100); (D) CK(focal +) (x100).
case_images: pore-29-1610983-g002.jpg
case_images: PMC10021297_04_pore-29-1610983-g002.jpg
case_images: F2
case_images: PARP inhibitor-related genes had no mutations (BRCA1/2 no mutations, HRD score 0 (Supplementary Figure S2)).
case_images: (A) HE(x100); (B) Vimentin(+) (x100); (C) CD68(OGC+) (x100); (D) CK(+) (x100).
case_images: pore-29-1610983-g003.jpg
case_images: PMC10021297_04_pore-29-1610983-g003.jpg
case_images: F3
case_images: Immunotherapy-related gene mutations were observed negative PD-1 immunohistochemistry results (TPS <1%, CPS = 5) and a low tumor mutational burden (TMB) (Supplementary Figure S3A) at 3.35 Muts/Mb, which occur in less 76% of pancreatic cancer patients. Microsatellite analysis showed microsatellite stability (MSS) (Supplementary Figure S3B) and negative EBV test results.
case_images: (A) HE (x100); (B) Vimentin (intraepithelial carcinoma -, anaplastic +) (x100); (C) CD68(+) (anaplastic +) (x100); (D) CK(intraepithelial carcinoma +, few anaplastic +) (x100).
case_images: pore-29-1610983-g004.jpg
case_images: PMC10021297_04_pore-29-1610983-g004.jpg
case_images: F4
case_images: Immunohistochemical staining (as in Figure 4) revealed the following Vim (intraepithelial carcinoma -, anaplastic +), CK (intraepithelial carcinoma +, few anaplastic +), EMA (intraepithelial carcinoma +), CK7 (intraepithelial carcinoma +), CK8/8 (intraepithelial carcinoma +), CD68 (anaplastic +), CK20 (-), CR (subepithelial mesenchymal +), des (subepithelial mesenchymal +), Muc-1 (intraepithelial carcinoma +), Muc-2 (-), P53 (anaplastic +20%), and Ki-67 (intraepithelial carcinoma +80%, anaplastic +70%).